Table 4.
Prevalence of resistance phenotypes to major antimicrobial classes among 172 nitocefin positive isolates.
| Resistance Phenotype | Number of isolates | % | |
|---|---|---|---|
| Multidrug resistant (MDR) phenotypes | AMP, SXT, TET | 8 | 4.65 |
| AMP, AMC, FOX, SXT, TET | 8 | 4.65 | |
| AMP, AMC, FOX, CHL, TET | 7 | 4.07 | |
| AMP, AMC, FOX, CHL, SXT, TET | 4 | 2.33 | |
| AMP, AMC, FOX, CHL, SXT | 4 | 2.33 | |
| AMP, AMC, CHL, TET | 2 | 1.16 | |
| AMP, CHL, SXT, TET | 2 | 1.16 | |
| AMP, AMC, SXT, TET | 2 | 1.16 | |
| AMP, AMC, CHL, SXT, TET | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CPO, CHL, SXT, TET | 2 | 1.16 | |
| AMP, CHL, TET | 2 | 1.16 | |
| AMP, FOX, CHL, TET | 2 | 1.16 | |
| Others with only one representative | 9 | 5,22 | |
| Sub-total | 54 | 31.40 | |
| Non-multidrug resistant (MDR) phenotypes | AMP | 38 | 22.09 |
| AMP, TET | 19 | 11.05 | |
| AMP, AMC, FOX, SXT | 8 | 4.65 | |
| AMP, AMC, FOX, TET | 7 | 4.07 | |
| AMP, AMC, FOX | 6 | 3.49 | |
| AMP, AMC, TET | 5 | 2.91 | |
| AMP, SXT | 5 | 2.91 | |
| AMP, AMC | 4 | 2.33 | |
| AMP, AMC, FOX, CEPH3, ATM | 4 | 2.33 | |
| AMP, AMC, FOX, CEPH3, CPO, ATM | 4 | 2.33 | |
| AMP, FOX, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CARB, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CPO, CARB, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, SXT | 2 | 1.16 | |
| Others with only one representative | 8 | 4.64 | |
| Sub-Total | 118 | 68.60 | |
| Total | 172 | 100 | |